A simple hplc-uv method development and validation for the quantification of dexibuprofen applied in bioequivalence study

Journal of Liquid Chromatography and Related Technologies

Volumn 35, Issue 13, 2012, Pages 1798-1811

  Loya, Punnamchand ^a   Saraf, Madhusudan N ^a  

^a BOMBAY COLLEGE OF PHARMACY   (India)

Author keywords

bioequivalence study; dexibuprofen; HPLC UV; human plasma; rapid; simple

Indexed keywords

BIOEQUIVALENCE STUDY; DEXIBUPROFEN; HPLC-UV; HUMAN PLASMAS; RAPID; SIMPLE;

ACETONITRILE; METHANOL; PHARMACOKINETICS; PLASMA (HUMAN); POTASSIUM;

HIGH PERFORMANCE LIQUID CHROMATOGRAPHY;

DEXIBUPROFEN;

AREA UNDER THE CURVE; ARTICLE; BIOEQUIVALENCE; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG HALF LIFE; DRUG STABILITY; DRUG STRUCTURE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; LIMIT OF DETECTION; LIMIT OF QUANTITATION; MALE; MAXIMUM PLASMA CONCENTRATION; NORMAL HUMAN; TIME TO MAXIMUM PLASMA CONCENTRATION; ULTRAVIOLET RADIATION;

EID: 84864863401     PISSN: 10826076     EISSN: 1520572X     Source Type: Journal    
DOI: 10.1080/10826076.2011.627602     Document Type: Article

References (17)

1. Sweetman, S. C. Martindale-The Complete Drug Reference, 36th ed.; Pharmaceutical Press: London, 2009; 39.
2. Kaehler, S. T.; Phleps, W.; Hesse, E. Dexibuprofen: Pharmacology, Therapeutic Uses and Safety. Inflammopharmacology 2003, 11, 371-383. (Pubitemid 38175946)
3. Evans, A. M. Enantioselective Pharmacodynamics and Pharmacokinetics of Chiral Nonsteroidal Anti-Inflammatory Drugs. Eur. J. Clin. Pharmacol. 1992, 42, 237-256.
4. Leising, G.; Resel, R.; Stelzer, F. Physical Aspects of Dexibuprofen and Racemic Ibuprofen. J. Clin. Pharmacol. 1996, 36, 3-6.
5. Langman, M. J. S.; Weil, J.; Wainright, P. Risks of Bleeding Peptic Ulcer Associated with Individual Non-Steriodal Anti-Inflammatory Drugs. Lancet. 1994, 343, 1075-1078.
6. Rainsford, K. D. Pharmacology and Toxicology of Ibuprofen. In Ibuprofen, a Critical Bibliographic Review; Taylor & Francis: London, 1999, pp 145-275.
7. Eller, N.; Kollenz, C. J.; Shiel, S.; Kikuta, C.; Mascher, M. Pharmacokinetics of Dexibuprofen Administered as 200 and 400mg Film Coated Tablet in Healthy Male Volunteers. Intern. J. Clin. Pharmacol. Therap. 1998, 36, 414-417. (Pubitemid 28395682)
8. Gabard, B.; Nirnberger, G.; Schiel, H.; Mascher, H.; Kikuta, C. H.; Mayer, J. M. Comparison of the Bioavailability of Dexibuprofen Administered Alone or as Part of Racemic Ibuprofen. Eur. J. Clin. Pharmacol. 1995, 48, 505-511.
9. Ikegawa, S.; Murao, N.; Oohashi, J.; Goto, J. Separatory Determination of Diastereomeric Ibuprofen Glucuronides in Human Urine by Liquid Chromatography=Electrospray Ionization-Mass Spectrometry. Biomed Chromatogr. 1998, 6, 317-321. (Pubitemid 28542596)
10. Ahn, H. Y.; Shiu, G. K.; Trafton, W. F.; Doyle, T. D. Resolution of the Enantiomers of Ibuprofen; Comparison Study of Diastereomeric Method and Chiral Stationary Phase Method. J. Chromatogr. B 1994, 653, 163-169. (Pubitemid 24085055)
11. Li-yan, M.; Zhang, H.; Zhong, W.; Shengpeng, D. Determination of Dexibuprofen Concentration and Pharmacokinetics in Ventricle Succus by HPLC-RP Method. Acta Academiae Medicinae Suzhou. 2004, 3, 318-320.
12. Center for Drug Evaluation and Research (CDER). Guidance for Industry. Bioanalytical Method Validation. Department of Health and Human Services. Food and Drug Administration Rockville, Maryland: U.S. 2001. [http://www.fda.gov/ cder/guidance/index.html].
13. Central Drug Standard Control Organization, (CDSCO). Schedule Y (Amended version). Directorate General of Health Services, Ministry of Health and Family Welfare, Govt. of India. 2005. www.cdsco. nic.in
14. ICH Harmonized Tripartite Guideline for Good Clinical Practice, Brookwoood Medical Publication Ltd.: Surrey, UK. 1996, pp 1-45.
15. Bolton, S. Pharmaceutical Statistics Practical and Clinical Applications, 3rd ed.; Marcel Dekker Inc.: New York, 1997, Vol. 80, pp 384-443.
16. Center for Drug Evaluation and Research (CDER). Guidance for Industry Statistical Approaches in Establishing Bioequivalence. Department of Health and Human Services. Food and Drug Administration. Rockville, Maryland: U.S. 2001. [http://www.fda.gov/cder/guidance/index.html].
17. FDA. In vivo bioequivalence guidances. Pharmacopeial Forum, US Department of Health and Human Service, Food and Drug Administration, Rockville, MD, USA, 1993, 19, 6501-6508.